Timothy Greenamyre, MD, PhD, Chair
Dr. Tim Greenamyre is the Love Family Professor and vice-chair of neurology, chief of Movement Disorders and director of the Pittsburgh Institute for Neurodegenerative Diseases (PIND) and the American Parkinson Disease Association Advanced Center for Parkinson’s Disease Research at the University of Pittsburgh. His laboratory studies mechanisms of neurodegeneration in Parkinson’s, with a focus on gene-environment interactions, along with translational studies use pharmacological and ‘gene therapy’ approaches. Dr. Greenamyre is a member of the Scientific Advisory Board of the Parkinson’s Foundation, Michael J. Fox Foundation and the American Parkinson Disease Association. He has been listed as one of the ‘Best Doctors in America’ since the mid-1990s and is editor-in-chief of the scientific journal Neurobiology of Disease.
Richard Smeyne, PhD, Co-Chair
Dr. Richard Smeyne is a Professor in the Jack and Vickie Farber Institute for Neuroscience at Thomas Jefferson University. His research focuses on the cell biology of Parkinson's, with an interest in the interactions between the immune system and the central nervous system (brain and spinal cord). With a long-standing interest in the cell biology of Parkinson’s disease, his studies examine both environmental and genetic causation. His lab was the first to show, in animal models of PD, that exercise could modify disease progression and more recently examines the underlying molecular programs r esponsible for this neuroprotection along with which cells are responsible for the toxicity seen following MPTP administration. Additionally, Dr. Smeyne studies the role of environmental enrichment in neuroprotection. He is also recognized for his work examining interactions of the peripheral immune system with that of the brain’s innate immune system immune as well as the role of viruses in the etiology of Parkinson’s. He has been published in Nature, Science, Proceedings of the National Academy of Sciences, Cell and the Journal of Neuroscience. Dr. Smeyne received his doctorate in anatomy from Thomas Jefferson University and completed his postdoctoral training in molecular biology at the Roche Institute of Molecular Biology.
A. Jon Stoessl, CM, MD, FRCPC, FCAHS
Dr. A. Jon Stoessl is Professor & Head of Neurology and Co-Director of the Djavad Mowafaghian Centre for Brain Health at UBC & Vancouver Coastal Health. He holds a Tier 1 Canada Research Chair in Parkinson’s and was previously the Director of the Pacific Parkinson’s Research Centre and Parkinson’s Foundation Centre of Excellence at UBC. Dr. Stoessl is Deputy Editor of the Movement Disorders Journal and sits on the editorial boards of Lancet Neurology, Journal of Parkinson’s Disease and Parkinsonism & Related Disorders. He was previously Chair of the Scientific Advisory Board of the Parkinson’s Foundation, as well as past Chair of the Scientific Advisory Boards of the Parkinson Society of Canada and Ontario Mental Health Foundation. He has served on the Interdisciplinary Adjudication Committee of the Canada Research Chairs program and the Mentoring Committee of the Parkinson Study Group. Dr. Stoessl serves on the Board of the International Association of Parkinsonism & Related Disorders, co-chairs the Steering Committee for the World Parkinson Congress, is President of the World Parkinson Coalition, previously served on the International Executive Committee of the Movement Disorders Society and chaired the MDS Awards Committee. He is a Member of the Order of Canada and a Fellow of the Canadian Academy of Health Sciences. Dr. Stoessl’s research involves the use of positron emission tomography (PET) to study Parkinson's disease and related disorders, including the use of imaging as a biomarker, the basis for complications of treatment and mechanisms of the placebo effect.
Roy Alcalay, MD, MS
Dr. Roy Alcalay is an Associate Professor of Neurology at the Taub Institute and the program director of the Movement Disorders Fellowship at the Columbia University Medical Center, a Center of Excellence. His research focuses on biomarkers and genetics in Parkinson’s disease and cognitive functioning. He is a Brookdale Leadership in Aging fellow, and his research is supported by the NIH, the Parkinson’s Foundation, the Michael J. Fox Foundation and the Smart Foundation. He is a member of Scientific Advisory Board (SAB) of the Parkinson’s Foundation and the Silverstein Foundation for Parkinson’s with GBA. He is the lead investigator of PD GENEration, a Parkinson's Foundation flagship study that provides genetic testing and counseling to people with Parkinson’s. His clinical practice focuses on Parkinson's and other movement disorders, including tremor, dystonia, Tourette syndrome, myoclonus, ataxia, and chorea. Dr. Alcalay has contributed to a range of original articles in leading medical research journals, including the The New England Journal of Medicine, Neurology, Archives of Neurology, Genetics in Medicine, Journal of Clinical and Experimental Neuropsychology, Movement Disorders and Parkinsonism and Related Disorders. Dr. Alcalay received his medical degree from Tel Aviv University, Israel, his neurology training from the Harvard University residency program at Massachusetts General Hospital and Brigham and Women's Hospital and his movement disorders training at Columbia University. He is a graduate of the Patient Oriented Research and earned Master's in biostatistics from Columbia University.
Robert Edwards, MD
Dr. Robert Edwards is the Cahill Professor of Neurology and Physiology at the University of California, San Francisco (UCSF), a Center of Excellence. Dr. Edwards is a neuroscientist recognized for his work on the molecular and cellular basis of neurotransmitter transporters and Parkinson’s disease. He is particularly known for identification of the proteins that transport classical transmitters into neurosecretory vesicles and for his work on their mechanism, regulation and physiological roles. His work now extends to the phenomena of neurotransmitter corelease, dense core vesicle formation and the function of alpha-synuclein. Dr. Edwards was born in New York City, attended Yale College and Johns Hopkins Medical School. He trained in clinical neurology, studied as a postdoctoral fellow with William J. Rutter at UCSF and joined the faculty at UCLA before returning to UCSF in 1995. He is a member of the National Academy of Medicine and the National Academy of Sciences.
Jennifer Goldman, MD, MS
Dr. Jennifer G. Goldman is the Section Chief for Parkinson’s Disease and Movement Disorders Rehabilitation at the Shirley Ryan Ability lab and Professor of Physical Medicine and Rehabilitation and Neurology at Northwestern University Feinberg School of Medicine. Dr. Goldman is a Movement Disorders neurologist with board certification in Behavioral Neurology and Neuropsychiatry. She is a clinician-researcher who has been a pioneer in the cognitive and behavioral aspects of PD and movement disorders and a longstanding champion of interdisciplinary care. Her work focuses on advancing our understanding of the non-motor and motor features of PD and movement disorders, using neuroimaging and biomarkers, and on developing pharmacological and non-pharmacological interventions to improve or prevent these symptoms. Dr. Goldman has been funded by NIH, Parkinson’s Foundation, Michael J. Fox Foundation, among others and is widely published. As a clinician, Dr. Goldman is passionate about offering a holistic, comprehensive, and interdisciplinary team-based approach for people with PD and movement disorders and their care partners. She graduated from Princeton University and received her MD from Northwestern University Medical School. She completed her neurology residency training at Washington University in St. Louis, followed by a movement disorder fellowship and a Master of Science degree in clinical research at Rush University in Chicago.
Matthew LaVoie, PhD
Dr. Matthew LaVoie is an Associate Professor of Neurology at Brigham and Women's Hospital and Harvard Medical School. Dr. LaVoie's lab is dedicated to uncovering the early molecular events responsible for the selective neurodegeneration and unique neuropathology associated with Parkinson's disease. A major goal of the lab is to understand the basic physiological functions of genes associated with familial Parkinson's, and the impact of their pathogenic mutations. Dr. LaVoie serves on the Scientific Advisory Board for the Parkinson's Foundation and the National Scientific Advisory Council for the American Foundation for Aging Research. He served on the Editorial Board of the Journal of Biological Chemistry and is currently the Editor-in-Chief of Brain Research. In addition to his responsibilities as Principal Investigator of a basic research laboratory at Brigham, he was the co-founder and co-director (with Dr. Barbara Bierer) of the Brigham Research Leadership Program and founder of the Career Building at a Research Hospital seminar series. Dr. LaVoie received his BA and BS in Biology and Psychology from Rutgers University and his PhD from the University of Pittsburgh.
Connie Marras, MD, PhD, FRCPC
Dr. Connie Marras is an Associate Professor of Neurology at the University of Toronto and a neurologist at the Toronto Western Hospital Movement Disorders Centre, a Parkinson’s Foundation Center of Excellence. She also serves as an associate editor for the Movement Disorders Journal, Executive Committee member of the Pan-American section of the Movement Disorders Society, and vice-chair of the research ethics board of the University Health Network in Toronto. Areas of research focus include the epidemiology and clinical expression of Parkinson’s disease and evaluating clinical assessment tools in Parkinson’s disease. Dr. Marras attended the University of Toronto where she initially trained in neurology and movement disorders and went on to obtain a PhD in epidemiology. She further trained in epidemiologic research methods at the Parkinson’s Institute in California.
Ian Reynolds, PhD
Dr. Ian Reynolds is the Chief Executive Officer of Rewind Therapeutics. Dr. Reynolds' interests are focused on drug discovery for neurological and neurodegenerative diseases. Previously, Dr. Reynold’s led the CNS Discovery group at Teva Pharmaceuticals. At Knopp, he led the team investigating the mechanism of action of dexpramipexole, which was in development for disease modification in amyotrophic lateral sclerosis (ALS). In that position, Dr. Reynolds ran the biology group that was working on dexpramipexole, as well as other CNS targets. At Merck, he was responsible for drug discovery groups working on Parkinson's, Stroke, and Alzheimer's disease and ophthalmology. Dr. Reynolds has extensive experience in academic research focused on neurodegenerative disease, including Parkinson's and stroke. The academic expertise includes substantial time leading and administering graduate education in pharmacology and neuroscience. Dr. Reynolds received his BSc from the University of Leeds, his PhD from the Johns Hopkins University School of Medicine and completed his post-doctoral fellowship in Neuropharmacology at the University of Chicago.
Margaret Rice, PhD
Dr. Margaret Rice is a Professor in the Department of Neurosurgery and the Department of Neuroscience and Physiology at New York University School of Medicine, a Center of Excellence. Dr. Rice's research in her laboratory is focused on regulation of dopamine, a key transmitter in motor and reward pathways in the brain. The Rice group uses carbon-fiber microelectrodes with fast-scan cyclic voltammetry to provide real-time monitoring of axonal dopamine release in dorsal and ventral striatum, and somatodendritic release in the substantia nigra and ventral tegmental area, primarily in brain slices. Current research is centered on a novel finding from the Rice group that hydrogen peroxide (H2O2), produced by mitochondrial respiration, is an endogenous regulator of synaptic and somatodendritic dopamine release, as well as dopamine neuron activity in the substantia nigra. The Rice group also studies regulation of axonal dopamine release by glutamate, GABA, calcium, cannabinoids and caffeine, the mechanism and regulation of somatodendritic dopamine release and dopamine dysfunction in transgenic mouse models of dystonia and PD. Dr. Rice received her BS from the University of Oklahoma and her PhD from the University of Kansas. Her post-doctoral training was done at NYU School of Medicine.
Stephen Shea, PhD
Dr. Stephen Shea is an Associate Professor at Cold Spring Harbor Laboratory. Dr. Shea's lab studies the neural circuitry underlying social communication and decisions. He uses natural social communication behavior in mice as a model to understand circuits and processes that are evolutionarily conserved and therefore shared broadly across species, likely contributing to disorders such as autism. Shea and colleagues have examined how emotion and arousal enable mice, via their olfactory systems, to store memories of other individuals and of related social signals. Recently, the lab made a key breakthrough, developing the ability to record from GCs in awake animals and discovering that their activity is dramatically modulated by state of consciousness. Finally, the Shea lab completed a series of studies of a different form of social recognition: auditory recognition of pup vocalizations by their mothers. Through this research, they have shown that a mouse model of Rett syndrome exhibits deficits in communication and learning not unlike those in human patients. Dr. Shea received his BS from the University of Maryland College Park and his PhD from the University of Chicago.